As shown in Fig. 7A and B, the total number of tumor-infiltrating CD8+ T cells increased significantly following treatment with SR717@RGE-HFn NPs, while the numbers of CD8+ T cells in the PBS- and free SR717-treated groups were fairly similar and remained at a low level. The gene discussed is CD8A; the disease is neoplasm.